Cordant Inc’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cordant Inc’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54	Closed	–	–	312
2021 Q3	$0	Buy	+54	New	+$534	﹤0.01%	384

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cordant Inc's SGMO Position: Q4 2021 in Review

Cordant Inc sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2021, closing a stake of 54 shares.

Cordant Inc first reported a position in SGMO in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2021.

Cordant Inc reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2021 after selling out during the quarter.
Cordant Inc sold 54 SANGAMO THERAPEUTICS INC shares in Q4 2021.
Cordant Inc first reported a position in SANGAMO THERAPEUTICS INC in Q3 2021 and held it in 1 quarter.
Cordant Inc's SANGAMO THERAPEUTICS INC position peaked at $0 in Q3 2021.
193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2021.

Based on Cordant Inc's 13F filing for Q4 2021, filed 25 Jan 2022.